MediPrint® Ophthalmics Announces Successful Completion of Its Phase 2b Glaucoma Clinical Study with Positive Results.
MediPrint® Ophthalmics , a clinical-stage ocular drug delivery platform technology focused on transforming ocular drug delivery, announces the completion of its Glaucoma SIGHT-2, Phase 2b study.
- MediPrint® Ophthalmics , a clinical-stage ocular drug delivery platform technology focused on transforming ocular drug delivery, announces the completion of its Glaucoma SIGHT-2, Phase 2b study.
- The Phase IIb trial was an active-controlled, randomized, dose-finding, multi-center study, evaluating the Company’s lead candidate (LL-BMT1) versus a control group on bimatoprost 0.01% ophthalmic solution.
- SIGHT-2 study evaluated safety and efficacy of LL-BMT-1 in 28 patients diagnosed with open-angle Glaucoma for three weeks.
- “The successful completion of the study is an important milestone as it validates our company’s technology and will help address significant unmet need for patients suffering from Glaucoma or Ocular Hypertension.